All Articles

As a key architect of its global manufacturing retires, Alliance Laundry bets on financial discipline and investor savvy to drive its next growth cycle.

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

A Canadian firm is betting big on natural hydrogen, a clean energy source found underground. With new funding and political clout, is this the future?

A new grant program for police tech seems simple, but Veritone's partnership with Police1 is a shrewd move to overcome the biggest sales hurdle: budget.

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

Browser innovator Shift renews its $25K Impact Grant, fueling sustainable startups as the tech industry grapples with its growing environmental footprint.

While others chase fleeting trends, one Colorado agency built a decade of success on a radical idea: sustainability over scale. Here's the analysis.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

With the appointment of Roku and Viant veteran Tom Wolfe, Locality signals a major play to solve local TV's biggest challenges: fragmentation and opacity.

An analysis of 89 school districts reveals a new data-driven playbook for reducing chronic absenteeism, with major implications for EdTech and human capital.

Despite massive security investments, known vulnerabilities are wreaking havoc. A new report reveals why AI demands a shift from pre-production to runtime defense.

With an $18M Series A, Novellia is flipping the script on real-world data, empowering patients to solve a decades-old, multi-billion-dollar R&D bottleneck.

JFrog's inclusion in the Russell 3000 isn't just a corporate win; it's a signal of the market's new respect for the software supply chain's vital role.

As Recursion heads to a key investor conference, it must prove its AI-powered drug discovery platform can deliver financial results, not just scientific promise.

As Motorcar Parts of America preps its FY2026 report, investors await answers on declining revenue and the strategic review of its once-touted EV business.

The Dallas Cowboys are using a new device to build muscle. It’s part of a high-stakes trend where technology is redefining athlete recovery and longevity.

Ahead of its token launch, nGRND has drawn 855k gamers with a novel promise: rewards backed by preserved, unmined gold. Is this the future of Web3?

A novel probiotic, sourced from an elite athlete's gut, has navigated the FDA's complex regulatory maze, signaling a major shift for the entire industry.

Darigold's partnership with Actus Nutrition isn't a retreat, but a strategic masterstroke redefining the value of milk in a high-tech protein market.